Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.